NCNA

NuCana PLC

Price

$1.30

return (12m)

-67.58%

p/e

-0.29

p/bv

0.19

DIVIDEND YIELD

0.00%

NCNA price

NuCana

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment NCNA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-10.96%

3 months

-17.72%

1 year

-67.58%

2 years

-99.73%

5 years

-99.99%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals NCNA

Valuation

P/E

-0.29

Sector -3.51

Industry -3.51

P/BV

0.19

Sector 1.99

Industry 1.99

P/Revenue (PSR)

Sector 2.05

Industry 2.05

EV/EBITDA

4.64

Sector -215.71

Industry -215.71

EV/EBIT

4.54

Sector -46.22

Industry -46.22

P/EBITDA

-0.27

Sector -21.18

Industry -21.18

P/EBIT

-0.27

Sector -28.19

Industry -28.19

P/Total Assets

0.15

Sector 1.18

Industry 1.18

P/Net Current Assets

0.23

Sector -10.00

Industry -10.00

P/Working Capital

0.22

Sector 1.60

Industry 1.60

EPS

-4.53

Sector -1.80

Industry -1.80

BVPS

6.75

Sector 2.03

Industry 2.03

Efficiency

Gross Margin

0.00%

Sector 41.43%

Industry 41.43%

EBITDA Margin

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

Sector -4,221,130.86%

Industry -4,221,130.86%

Operating Margin

0.00%

Sector -35.37%

Industry -35.37%

Net Profit Margins

0.00%

Sector -36.08%

Industry -36.08%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-67.08%

Sector -57.16%

Industry -57.16%

ROA

-52.71%

Sector -59.52%

Industry -59.52%

ROIC

-413.00%

Sector -2,363.38%

Industry -2,363.38%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.73

Sector 2.91

Industry 2.91

Net Debt / EBITDA

5.79

Sector -14,058,646.59

Industry -14,058,646.59

Net Debt / EBIT

5.67

Sector -8.05

Industry -8.05

Net Debt / Equity

-0.96

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.00

Sector 0.00

Industry 0.00

Equity/Assets

0.79

Sector 0.46

Industry 0.46

Liabilities/Assets

0.21

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-20.05%

Sector -

Industry -

Fundamentals NCNA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NCNA NuCana PLC	$1.30	-68.67%	0.00%	-0.29	0.19	-67.08%	0.00%
JNJ Johnson & Johnson	$269.99	56.27%	1.96%	30.90	7.65	24.76%	21.48%
PFE Pfizer Inc.	$28.31	25.77%	6.08%	37.23	1.89	5.07%	6.80%
ABBV AbbVie Inc.	$263.16	23.44%	2.60%	73.78	-78.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.62	-27.65%	4.80%	9.44	5.02	53.11%	35.32%
MRK Merck & Co. Inc.	$147.79	92.78%	2.29%	114.37	8.64	7.56%	4.77%
AZN AstraZeneca PLC	$166.12	14.91%	1.95%	19.85	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.01	48.57%	4.09%	13.50	5.62	41.59%	18.87%
ZTS Zoetis Inc.	$69.90	-49.71%	2.99%	11.07	9.27	83.77%	27.69%
AMGN Amgen Inc.	$409.53	50.71%	2.43%	25.29	18.92	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$789.37	42.66%	0.47%	18.75	2.56	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$114.87	51.86%	0.00%	32.57	93.84	288.13%	24.86%
MCK McKesson Corporation	$863.15	14.07%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$521.52	38.47%	0.00%	30.03	6.53	21.76%	35.00%
CAH Cardinal Health Inc.	$220.60	44.54%	0.93%	30.18	-18.99	-62.92%	0.67%
ARGX argenx SE	$957.38	31.19%	0.00%	1.85	2.21	119.72%	44.81%
HRMY Harmony Biosciences Holdings Inc.	$41.02	53.29%	0.00%	13.11	2.38	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NCNA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT NuCana

NuCana PLC

Average Investor10 user rating

4.0 (0 people)

United States

29 years

Founded: 1997

2017

Time since IPO - 9 years

29

Employees

NuCana plc is a United Kingdom–based company operating in the healthcare sector, within the biopharmaceutical and oncology drug-development industry. The company focuses on developing cancer treatments using proprietary ProTide prodrug technology.

Its main areas of activity include:

• Development of modified chemotherapy agents using ProTide technology.
• Clinical research targeting gastrointestinal and aggressive cancers.
• Biomarker analysis and translational oncology research.
• Multi-country clinical trials in partnership with cancer centers.

Its portfolio is centered on prodrug candidates designed to improve cellular uptake, overcome drug resistance and reduce toxicity associated with conventional chemotherapy.

NuCana operates internationally, with research activities based in the United Kingdom and clinical trials conducted across Europe, the United States and other regions. Its structure includes medicinal-chemistry teams, clinical operations, regulatory units and collaborations with academic and medical institutions.

Industry dynamics affecting NuCana include advancements in oncology treatments, competition from immunotherapies and targeted therapies, clinical-development costs, regulatory frameworks, investor sentiment toward biotechnology and the need for differentiated therapeutic outcomes.

Shares of NuCana plc trade on the Nasdaq under the ticker NCNA.

History and Development

NuCana was founded in 2008 in Edinburgh, Scotland, with the objective of applying ProTide chemistry to oncology treatments.

In its early stages, the company focused on addressing limitations of traditional chemotherapy, including poor cellular delivery, resistance mechanisms and toxicity. Initial efforts centered on developing preclinical programs to validate the application of ProTide technology in cancer therapies.

Throughout the 2010s, NuCana advanced its lead drug candidates into clinical trials, targeting cancers with limited treatment options. The company expanded its scientific capabilities and established international trial networks.

In recent years, NuCana has operated in a highly competitive and capital-intensive biotechnology environment, refining its pipeline based on clinical data and strengthening research collaborations. The company has continued investing in biomarker research and exploring new applications of its ProTide platform for difficult-to-treat cancers.

Additional Information

NuCana PLC (United States) is listed on the Nasdaq and has a market capitalization of $5.20 million, with shareholders equity totaling $27.01 million.

The company employs approximately 29 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, NuCana PLC reported $- in revenue, generating net income of $-18.12 million.

Key financial metrics include a P/E ratio of -0.29, a price-to-book (P/B) ratio of 0.19, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NCNA.

Market cap

$5.20 million

Net worth

$27.01 million

$27,013,000.00

Assets

$34.38 million

$34,377,000.00

Total Shares Outstanding

4.00 million

4,000,000

Average Daily Trading Volume

$55.62 Thousand

$55,616.00

Sector

Health Care

Industry

Biotechnology

NCNA

NCNA revenue and profits

Financial Results NCNA

DRAG THE FRAME TO SEE MORE DATA

NCNA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$866.64 14,53% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$220.22 45,11% (12M)

P/E

30.18

0.93%

ROE

-62.92%

P/BV

-18.99

JNJ - Johnson & Johnson

$271.22 54,34% (12M)

P/E

30.90

1.96%

ROE

24.76%

P/BV

7.65

ABBV - AbbVie

$264.40 23,67% (12M)

P/E

73.78

2.60%

ROE

-106.44%

P/BV

-78.53

MRK - Merck & Co.

$148.78 96,81% (12M)

P/E

114.37

2.29%

ROE

7.56%

P/BV

8.64

AZN - AstraZeneca

$166.58 14,30% (12M)

P/E

19.85

1.95%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$28.67 29,16% (12M)

P/E

37.23

6.08%

ROE

5.07%

P/BV

1.89

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$866.64 14,53% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$220.22 45,11% (12 M)

P/L

30.18

0.93%

ROE

-62.92%

P/VP

-18.99

JNJ - Johnson & Johnson

$271.22 54,34% (12 M)

P/L

30.90

1.96%

ROE

24.76%

P/VP

7.65

ABBV - AbbVie

$264.40 23,67% (12 M)

P/L

73.78

2.60%

ROE

-106.44%

P/VP

-78.53

MRK - Merck & Co.

$148.78 96,81% (12 M)

P/L

114.37

2.29%

ROE

7.56%

P/VP

8.64

AZN - AstraZeneca

$166.58 14,30% (12 M)

P/L

19.85

1.95%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$28.67 29,16% (12 M)

P/L

37.23

6.08%

ROE

5.07%

P/VP

1.89

Frequently Asked Questions

What is the price of NuCana (NCNA) today?

The current price of NuCana (NCNA) is $1.30. The stock began the year trading around $3.60 and is currently priced at $1.30. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does NuCana (NCNA) pay dividends?

NuCana (NCNA) did not pay dividends over the past year.

Is NuCana (NCNA) a good investment?

NuCana (NCNA) is currently trading at $1.30 with a P/E ratio of -0.29. This represents a -13% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -67.58%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy NuCana (NCNA) stock?

You can buy NuCana (NCNA) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol NCNA and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of NuCana (NCNA) yield today?

Over the past month, NuCana (NCNA) has returned -10.96% — -67.58% over the past year, and -99.99% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of NuCana (NCNA) today at the current price of $1.30 your total investment would be $130.00.

Based on historical performance, the investment would have grown to approximately:

$42.15 after 1 year
$0.01 after 5 years
$130.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

NCNA

NuCana PLC

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment NCNA

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING NCNA WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT NuCana

NuCana PLC

United States

29 years

2017

29

History and Development

Additional Information

PROFIT X PRICE NCNA

Financial Results NCNA

NCNA cash flow

Asset, Revenue and Profit Growth - NCNA

NCNA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions